Nuformix PLC
LSE:NFX
Nuformix PLC
Nuformix Plc is a pharmaceutical development company, which targets unmet medical needs in fibrosis and oncology via drug repurposing. The company is headquartered in Cambridge, Cambridgeshire and currently employs 3 full-time employees. The company went IPO on 2015-12-17. The firm focuses on medical needs in fibrosis and oncology using drug repurposing. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001, is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy induced nausea and vomiting). NXP002, is its pre-clinical lead asset and used for inhaled treatment for idiopathic pulmonary fibrosis (IPF). NXP004, is an oncology drug that is used for the treatment of several cancers. The firm's subsidiary is Nuformix Technologies Limited.
Nuformix Plc is a pharmaceutical development company, which targets unmet medical needs in fibrosis and oncology via drug repurposing. The company is headquartered in Cambridge, Cambridgeshire and currently employs 3 full-time employees. The company went IPO on 2015-12-17. The firm focuses on medical needs in fibrosis and oncology using drug repurposing. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001, is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy induced nausea and vomiting). NXP002, is its pre-clinical lead asset and used for inhaled treatment for idiopathic pulmonary fibrosis (IPF). NXP004, is an oncology drug that is used for the treatment of several cancers. The firm's subsidiary is Nuformix Technologies Limited.
